Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 695-938-6 | CAS number: 678966-16-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Oral: 50 mg/kg bodyweight < LD50 < 300 mg/kg bodyweight (actual value: 50 mg/kg bodyweight < LD50 < 300 mg/kg bodyweight) (OECD Guideline 423)
Dermal: 200 mg/kg < LD50 < 1000 mg/kg (actual value: 501 mg/kg in female rats, 926 mg/kg in male rats) (OECD Guideline 402)
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 2009-03-05 to 2009-04-03
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Version / remarks:
- 2001
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- no
- Specific details on test material used for the study:
- Batch No.: 08111121
Purity: 98% - Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 8 - 12 weeks
- Weight at study initiation: 213 - 239 g
- Fasting period before study: Yes (overnight prior to and approximately four hours after dosing)
- Housing: housed in groups of (up to) three rats of the same sex, in solid bottomed polycarbonate cages with a stainless steel mesh lid. Each cage contained a quantity of autoclaved wood flake bedding.
- Diet: free access to a standard rodent diet (Rat and Mouse No. 1 Maintenance Diet)
- Water: freely available
- Acclimation period: Minimum of five days.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19-23 °C
- Humidity (%): 40 - 70%
- Photoperiod (hrs dark / hrs light): 12 hours light, 12 hours dark - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 5 mg/mL and 30 mg/mL
DOSE VOLUME APPLIED: 10 mL/kg bodyweight
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: 300 mg/kg chosen as the starting dose for compliance with the guidelines. - Doses:
- Group 1: 300 mg/kg (3 females)
Group 2: 50 mg/kg (3 females)
Group 3: 50 mg/kg (3 females) - No. of animals per sex per dose:
- 3
- Control animals:
- no
- Details on study design:
- - Mortality: check the cages of rats at least twice daily for any mortalities
- Clinical observations: 14-day observation after dosing. The nature and severity, where appropriate, of the clinical signs and the time were recorded at each observation.
- Bodyweight: recorded on Days 1 (prior to dosing), 8 and 15. Individual weekly bodyweight changes and group mean bodyweights were calculated.
- Other examinations performed: necropsy, macropathology. - Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 50 - < 300 mg/kg bw
- Based on:
- test mat.
- Mortality:
- Two females dosed at 300 mg/kg died approximately 2 hours after dosing and a further female was killed for animal welfare reasons approximately 4 hours after dosing. Clinical signs prior to death comprised, underactive behaviour, seen in all animals. In addition loose faeces, hunched posture, piloerection, shallow respiration, reduced body temperature, unsteady gait, tremors and partially closed eyelids were all noted in two female. Reduced body tone and flat posture, were recorded for one female and increased respiration, chin rubbing, salivation and urine staining around the peri genital area in a further female . These signs were seen from approximately one hour after dosing. A loss in bodyweight was recorded for all three decedents. Macroscopic examination of the animals revealed yellow fluid contents of the stomach, duodenum, small and large intestines and caecum in all animals.
- Clinical signs:
- other: Clinical signs of reaction to treatment in animals dosed at 50 mg/kg comprised loose faeces, seen in five females. These signs were first noted approximately one hour after dosing. Recovery of animals, as judged by external appearance and behaviour, was c
- Gross pathology:
- Macroscopic examination at study termination on Day 15 revealed pallor of the lungs in three females treated at 50 mg/kg. No abnormalities were revealed in any other animal at the macroscopic examination at this time.
- Interpretation of results:
- Category 3 based on GHS criteria
- Conclusions:
- The acute median lethal oral dose (LD50) to rats of the test substance was demonstrated to be between 50 and 300 mg/kg bodyweight. The test substance is included in Category 3, according to the Globally Harmonised System (GHS), (UNITED NATIONS, 2005).
- Executive summary:
The study was performed to assess the acute oral toxicity of the test substance to the rat according to OECD Guideline 423.
A group of three fasted female rats received a single oral gavage dose of the test substance, formulated in dried corn oil, at a dose level of 300 mg/kg bodyweight. As results at this dose level indicated the acute median lethal dose to be below 300 mg/kg bodyweight, in compliance with the study guidelines, a further two groups of three fasted females were similarly dosed at 50 mg/kg bodyweight to complete the study.
Two females dosed at 300 mg/kg died approximately 2 hours after dosing and a further female was killed for animal welfare reasons approximately 4 hours after dosing. Clinical signs prior to death comprised, underactive behaviour, seen in all animals. In addition loose faeces, hunched posture, piloerection, shallow respiration, reduced body temperature, unsteady gait, tremors and partially closed eyelids were all noted in two females. Reduced body tone and flat posture, were recorded for one female and increased respiration, chin rubbing, salivation and urine staining around the peri genital area in a further female. These signs were seen from approximately one hour after dosing. A loss in bodyweight was recorded for all three decedents. Macroscopic examination of the animals revealed yellow fluid contents of the stomach, duodenum, small and large intestines and caecum in all animals.
Clinical signs of reaction to treatment in animals dosed at 50 mg/kg comprised loose faeces, seen in five females. These signs were first noted approximately one hour after dosing. Recovery of animals, as judged by external appearance and behaviour, was complete by Day 2. No clinical signs were seen in the remaining animal dosed at 50 mg/kg.
A low bodyweight gain was noted for two females on Day 15. All other animals were considered to have achieved satisfactory bodyweight gains throughout the study.
Macroscopic examination at study termination on Day 15 revealed pallor of the lungs in three females treated at 50 mg/kg. No abnormalities were revealed in any other animal at the macroscopic examination at this time.
The acute median lethal oral dose (LD50) to rats of the test substance was demonstrated to be between 50 and 300 mg/kg bodyweight. The test substance is included in Category 3, according to the Globally Harmonised System (GHS), (UNITED NATIONS, 2005).
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 50 mg/kg bw
- Quality of whole database:
- Guideline study, GLP study
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 2015-01-29 to 2015-04-16
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Version / remarks:
- 2004
- Deviations:
- no
- GLP compliance:
- no
- Remarks:
- non GLP, but in compliance with China National Metrology Accreditation
- Limit test:
- no
- Specific details on test material used for the study:
- Batch No.: 141104
Purity: 95.4% - Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 7 - 9 weeks.
- Weight at study initiation: 200 to 300 g.
- Housing: 5 per cage by sex
- Diet (e.g. ad libitum): Ad libitum
- Water (e.g. ad libitum): Ad libitum from bottled water
- Acclimation period: 6 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-26 °C
- Humidity (%): 40 - 70%
- Air changes (per hr): 10-12
- Photoperiod (hrs dark / hrs light): 12-hour light / dark cycle. - Type of coverage:
- occlusive
- Vehicle:
- vegetable oil
- Details on dermal exposure:
- TEST SITE
- Area of exposure: not less than 10% of the total body surface area
- Type of wrap if used: orthopedic stockinette.
REMOVAL OF TEST SUBSTANCE
- Washing (if done): Yes - washed with room temperature tap water
- Time after start of exposure: 24 hours
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): four dosage levels (215, 464, 1000, 2150 mg/kg) in female rats and male rats
- Concentration (if solution): N/A - administered as supplied - Duration of exposure:
- 24 h
- Doses:
- four dosage levels (215, 464, 1000, 2150 mg/kg) in female rats and male rats
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Mortality and clinical/behavioral signs of toxicity were made at least two times on the day of dosing (Day 0) and at least once thereafter for 14 days. Bodyweights were recorded just prior to dosing and on days 7 and 14.
- Necropsy of survivors performed: yes
- Other examinations performed: macroscopic pathology. - Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 501 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- > 344 - < 730
- Key result
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 926 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- > 636 - < 1 350
- Mortality:
- Death occurred in female rats at 464, 1000, 2150mg/kg levels and male rats at 1000, 2150mg/kg levels. The acute dermal LD50 wás estimated to be 501 mg/kg in female rats (95% confidence interval is 344 to 730mg/kg) and 926 mg/kg in male rats (95% confidence interval is 636 to 1350mg/kg). according to Horn's method.
- Clinical signs:
- other: During experiment observation, clinical signs such as tremors and subject skin with varying degrees of poisoning symptoms (nigrescence, edema, necrosis, easy off) were found in 215, 464, 1000, 2150 mg/kg dose group of male and female rats, after 3 days th
- Gross pathology:
- No abnormal necropsy findings occurred in any test animal which could be suspected to be due to the test substance.
- Interpretation of results:
- Category 3 based on GHS criteria
- Conclusions:
- The acute dermal LD50 was estimated to be 501 mg/kg in female rats (95% confidence interval is 344 to 730 mg/kg) and 926 mg/kg in male rats (95% confidence interval is 636 to 1350 mg/kg). Based on these results, it was concluded that application of the test substance was moderately toxic by acute dermal route.
- Executive summary:
The study was performed to assess the acute dermal toxicity of the test material in the Sprague-Dawley rat according to OECD Guideline 402: Acute Dermal Toxicity test (Ministry of Environmental Protection of the People's Republic of China, 2004).
The test material was evaluated for its acute dermal toxicity potential and relative skin irritancy in rats. 20 fernale and 20 male SD rats were randomly divided into 4 groups respectively for 24 hours by acute dermal route. Treated groups were dosed with the test material at 215, 464, 1000, 2150 mg/kg for female and male rat, respectively. Parameters measured during the exposure and observation period were body weight changes, clinical signs, mortality, and local irritation.
During experiment observation, clinical signs such as tremors and subject skin with varying degrees of poisoning symptoms (nigrescence, edema, necrosis, easy off) were found in 215, 464, 1000, 2150 mg/kg dose group of male and female rats, after 3 days the survivor appeared a black scab which was start off in 6 weeks and then returned to recovery. Death occurred in female rats at 464, 1000, 2150 mg/kg levels and male rats at 1000, 2150 mg/kg levels.
The acute dermal LD50 was estimated to be 501 mg/kg in female rats (95% confidence interval is 344 to 730 mg/kg) and 926 mg/kg in male rats (95% confidence interval is 636 to 1350 mg/kg). Based on these results, it was concluded that application of the test substance was moderately toxic by acute dermal route.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 501 mg/kg bw
- Quality of whole database:
- Guideline study, non GLP, but in compliance with China National Metrology Accreditation
Additional information
Acute oral toxicity:
The study was performed to assess the acute oral toxicity of the test substance to the rat according to OECD Guideline 423.
A group of three fasted female rats received a single oral gavage dose of the test substance, formulated in dried corn oil, at a dose level of 300 mg/kg bodyweight. As results at this dose level indicated the acute median lethal dose to be below 300 mg/kg bodyweight, in compliance with the study guidelines, a further two groups of three fasted females were similarly dosed at 50 mg/kg bodyweight to complete the study.
Two females dosed at 300 mg/kg died approximately 2 hours after dosing and a further female was killed for animal welfare reasons approximately 4 hours after dosing. Clinical signs prior to death comprised, underactive behaviour, seen in all animals. In addition loose faeces, hunched posture, piloerection, shallow respiration, reduced body temperature, unsteady gait, tremors and partially closed eyelids were all noted in two females. Reduced body tone and flat posture, were recorded for one female and increased respiration, chin rubbing, salivation and urine staining around the peri genital area in a further female. These signs were seen from approximately one hour after dosing. A loss in bodyweight was recorded for all three decedents. Macroscopic examination of the animals revealed yellow fluid contents of the stomach, duodenum, small and large intestines and caecum in all animals.
Clinical signs of reaction to treatment in animals dosed at 50 mg/kg comprised loose faeces, seen in five females. These signs were first noted approximately one hour after dosing. Recovery of animals, as judged by external appearance and behaviour, was complete by Day 2. No clinical signs were seen in the remaining animal dosed at 50 mg/kg.
A low bodyweight gain was noted for two females on Day 15. All other animals were considered to have achieved satisfactory bodyweight gains throughout the study.
Macroscopic examination at study termination on Day 15 revealed pallor of the lungs in three females treated at 50 mg/kg. No abnormalities were revealed in any other animal at the macroscopic examination at this time.
The acute median lethal oral dose (LD50) to rats of the test substance was demonstrated to be between 50 and 300 mg/kg bodyweight. The test substance is included in Category 3, according to the Globally Harmonised System (GHS), (UNITED NATIONS, 2005).
Acute inhalation toxicity:
No data were available for acute inhalation toxicity. However, given the extremely low vapour pressure of the substance, and there is acute dermal study is available, testing for acute inhalation toxicity is therefore not required.
Acute dermal toxicity:
The study was performed to assess the acute dermal toxicity of the test material in the Sprague-Dawley rat according to OECD Guideline 402: Acute Dermal Toxicity test (Ministry of Environmental Protection of the People's Republic of China, 2004).
The test material was evaluated for its acute dermal toxicity potential and relative skin irritancy in rats. 20 female and 20 male SD rats were randomly divided into 4 groups respectively for 24 hours by acute dermal route. Treated groups were dosed with the test material at 215, 464, 1000, 2150 mg/kg for female and male rat, respectively. Parameters measured during the exposure and observation period were body weight changes, clinical signs, mortality, and local irritation.
During experiment observation, clinical signs such as tremors and subject skin with varying degrees of poisoning symptoms (nigrescence, edema, necrosis, easy off) were found in 215, 464, 1000, 2150 mg/kg dose group of male and female rats, after 3 days the survivor appeared a black scab which was start off in 6 weeks and then returned to recovery. Death occurred in female rats at 464, 1000, 2150 mg/kg levels and male rats at 1000, 2150 mg/kg levels.
The acute dermal LD50 was estimated to be 501 mg/kg in female rats (95% confidence interval is 344 to 730 mg/kg) and 926 mg/kg in male rats (95% confidence interval is 636 to 1350 mg/kg). Based on these results, it was concluded that application of the test substance was moderately toxic by acute dermal route.
Justification for classification or non-classification
Oral: 50 mg/kg bodyweight < LD50 < 300 mg/kg bodyweight (actual value: 50 mg/kg bodyweight < LD50 < 300 mg/kg bodyweight)
Therefore in accordance with Regulation (EC) No. 1272/2008 (amended by 286/2011) Table 3.1.1, this substance should be classified as category 3 for this endpoint.
Specific target organ toxicity-single exposure:
No significant non-lethal toxic effects observed in acute oral toxicity study.
Therefore in accordance with Regulation (EC) No. 1272/2008 Table 3.8.1, this substance should not be classified for this endpoint.
Dermal: 200 mg/kg < LD50 < 1000 mg/kg (actual value: 501 mg/kg in female rats, 926 mg/kg in male rats)
Therefore in accordance with Regulation (EC) No. 1272/2008 (amended by 286/2011) Table 3.1.1, this substance should be classified as category 3 for this endpoint.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.